Author:
Abo El-Ela Fatma I.,Hassan Walid Hamdy,Amer Alaa M.,El-Dek S. I.
Abstract
AbstractMucormycosis is uncommon, yet it is more prevalent among individuals with underlying health conditions and those who are immunocompromised. Chitosan is studied because of its appealing properties and diverse applications. The purpose of this work is to synthesize chitosan nanoparticles (CSNPs) by ionic gelation method at various pH levels and test them against Mucor and other filamentous fungus. Field Emission Scanning Electron Microscope, Zeta sizer, Zeta potential, and Fourier Transformed Infrared Spectroscopy were used to characterize CSNPs. Hydrodynamic size increased considerably with increasing pH. Our CSNPs were tested against fungal isolates of Aspergillus Flavus RCMB 02783, Aspergillus Fumigatus RCMB 02564, and Aspergillus Niger RCMB 02588, Penicillium Notatum (NCPF 2881) and (M. circinelloides CNRMA 03.894) causing mucromycosis. Antifungal activity was investigated using Minimum inhibitory concentration (MIC), Minimum Fungicidal concentration (MFC), Disc diffusion assay, and Antifungal inhibitory percentages methods. The best antifungal efficacy results were obtained through CSNPs prepared at pH = 4.4 at very low concentration for MIC (1.03 or 2.75 μg/mL) with 100% M. circinelloides inhibition followed by pH = 4.6 with MIC (73 or 208 μg/mL) and 93% M. cirecinelloides inhibition %. Future usage of these materials in masks or wound dressing to avoid fungal infections, including mucormycosis following COVID-19, penicillium, and aspergillosis toxicity and infections.
Graphical Abstract
Publisher
Springer Science and Business Media LLC
Subject
Applied Microbiology and Biotechnology,General Medicine,Microbiology
Reference50 articles.
1. Ostrosky-Zeichner L, Casadevall A, Galgiani JN, Odds FC, Rex JH (2010) An insight into the antifungal pipeline: selected new molecules and beyond. Nat Rev Drug Discov 9(9):719–727. https://doi.org/10.1038/nrd3074
2. Agarwal A et al (2008) Genomic and genetic approaches for the identification of antifungal drug targets. Infect Disord - Drug Targets 8(1):2–15. https://doi.org/10.2174/187152608784139613
3. A. Carrillo-Munoz, G. Giusiano, P. Ezkurra, G. Q.-R. E. Quimioter, and undefined (2006) Antifungal agents: mode of action in yeast cells. seq.es 19(2): 130–139. https://seq.es/wp-content/uploads/2010/06/seq_0214-3429_19_2_revision_carrillo_munoz.pdf. Accessed 31 Dec 2021
4. Rajeshkumar R, Sundararaman M (2012) Emergence of Candida spp. and exploration of natural bioactive molecules for anticandidal therapy–status quo. Mycoses 55(3):e60–e73. https://doi.org/10.1111/J.1439-0507.2011.02156.X
5. Schmidt B, Ribnicky DM, Poulev A, Logendra S, Cefalu WT, Raskin I (2008) A natural history of botanical therapeutics. Metab-Clin Exp 57(SUPPL. 1):S3–S9. https://doi.org/10.1016/J.METABOL.2008.03.001
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献